Clinical Trial Update: A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets [Phase 4]

View source ↗

Summary

Phase 4 bioequivalence study comparing a new alprazolam dropped formulation to standard alprazolam tablets; study completed in healthy subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Individuals

Drugs mentioned

• alprazolam (dropped formulation) (alprazolam)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Healthy | Phase 4 | Status: COMPLETED